Therapy Areas
Sanofi granted non-exclusive license to Scribe Therapeutics' genome editing technology
27 September 2022 -

Molecular engineering company Scribe Therapeutics Inc announced on Tuesday a new research collaboration with French healthcare company Sanofi SA (Euronext Paris: SAN) (NASDAQ: SNY).

Under the agreement Sanofi will use Scribe's CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer.

Sanofi is granted non-exclusive rights to Scribe's CasX-Editor (XE) technology for multiple oncology targets in exchange for a USD25m upfront fee with the potential for more than USD1bn in milestone payments, as well as tiered royalties on net future sales of any products that may result from this research agreement.



Related Headlines